Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 182

1.

Multicolor Flow Cytometry and Cytokine Analysis Provides Enhanced Information on Kidney Transplant Biopsies.

Muczynski KA, Leca N, Anderson AE, Kieran N, Anderson SK.

Kidney Int Rep. 2018 Mar 3;3(4):956-969. doi: 10.1016/j.ekir.2018.02.012. eCollection 2018 Jul.

2.

Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy.

Kurokawa C, Iankov ID, Anderson SK, Aderca I, Leontovich AA, Maurer MJ, Oberg AL, Schroeder MA, Giannini C, Greiner SM, Becker MA, Thompson EA, Haluska P, Jentoft ME, Parney IF, Weroha SJ, Jen J, Sarkaria JN, Galanis E.

J Natl Cancer Inst. 2018 May 16. doi: 10.1093/jnci/djy033. [Epub ahead of print]

PMID:
29788332
3.

Molecular Mechanisms of Nitric Oxide in Cancer Progression, Signal Transduction, and Metabolism.

Somasundaram V, Basudhar D, Bharadwaj G, No JH, Ridnour LA, Cheng RYS, Fujita M, Thomas DD, Anderson SK, McVicar DW, Wink DA.

Antioxid Redox Signal. 2018 May 2. doi: 10.1089/ars.2018.7527. [Epub ahead of print]

PMID:
29634348
4.

Association of TNFRSF1B Promoter Polymorphisms with Human Disease: Further Studies Examining T-Regulatory Cells Are Required.

Li H, Anderson SK.

Front Immunol. 2018 Mar 6;9:443. doi: 10.3389/fimmu.2018.00443. eCollection 2018.

5.

Identification of an elaborate NK-specific system regulating HLA-C expression.

Li H, Ivarsson MA, Walker-Sperling VE, Subleski J, Johnson JK, Wright PW, Carrington M, Björkström NK, McVicar DW, Anderson SK.

PLoS Genet. 2018 Jan 12;14(1):e1007163. doi: 10.1371/journal.pgen.1007163. eCollection 2018 Jan.

6.

Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572.

Schiff D, Jaeckle KA, Anderson SK, Galanis E, Giannini C, Buckner JC, Stella P, Flynn PJ, Erickson BJ, Schwerkoske JF, Kaluza V, Twohy E, Dancey J, Wright J, Sarkaria JN.

Cancer. 2018 Apr 1;124(7):1455-1463. doi: 10.1002/cncr.31219. Epub 2018 Jan 3.

PMID:
29313954
7.

Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02.

Galanis E, Anderson SK, Miller CR, Sarkaria JN, Jaeckle K, Buckner JC, Ligon KL, Ballman KV, Moore DF Jr, Nebozhyn M, Loboda A, Schiff D, Ahluwalia MS, Lee EQ, Gerstner ER, Lesser GJ, Prados M, Grossman SA, Cerhan J, Giannini C, Wen PY; Alliance for Clinical Trials in Oncology and ABTC.

Neuro Oncol. 2018 Mar 27;20(4):546-556. doi: 10.1093/neuonc/nox161.

PMID:
29016887
8.

Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for Limited Brain Metastases: A Secondary Analysis of the North Central Cancer Treatment Group N0574 (Alliance) Randomized Controlled Trial.

Churilla TM, Ballman KV, Brown PD, Twohy EL, Jaeckle K, Farace E, Cerhan JH, Anderson SK, Carrero XW, Garces YI, Barker FG 2nd, Deming R, Dixon JG, Burri SH, Chung C, Ménard C, Stieber VW, Pollock BE, Galanis E, Buckner JC, Asher AL.

Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1173-1178. doi: 10.1016/j.ijrobp.2017.07.045. Epub 2017 Aug 5.

PMID:
28939223
9.

Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial.

Brown PD, Ballman KV, Cerhan JH, Anderson SK, Carrero XW, Whitton AC, Greenspoon J, Parney IF, Laack NNI, Ashman JB, Bahary JP, Hadjipanayis CG, Urbanic JJ, Barker FG 2nd, Farace E, Khuntia D, Giannini C, Buckner JC, Galanis E, Roberge D.

Lancet Oncol. 2017 Aug;18(8):1049-1060. doi: 10.1016/S1470-2045(17)30441-2. Epub 2017 Jul 4.

10.

Correction: Activating Receptor Signals Drive Receptor Diversity in Developing Natural Killer Cells.

Freund J, May RM, Yang E, Li H, McCullen M, Zhang B, Lenvik T, Cichocki F, Anderson SK, Kambayashi T.

PLoS Biol. 2016 Dec 29;14(12):e1002590. doi: 10.1371/journal.pbio.1002590. eCollection 2016 Dec.

11.

TET2 binds the androgen receptor and loss is associated with prostate cancer.

Nickerson ML, Das S, Im KM, Turan S, Berndt SI, Li H, Lou H, Brodie SA, Billaud JN, Zhang T, Bouk AJ, Butcher D, Wang Z, Sun L, Misner K, Tan W, Esnakula A, Esposito D, Huang WY, Hoover RN, Tucker MA, Keller JR, Boland J, Brown K, Anderson SK, Moore LE, Isaacs WB, Chanock SJ, Yeager M, Dean M, Andresson T.

Oncogene. 2017 Apr;36(15):2172-2183. doi: 10.1038/onc.2016.376. Epub 2016 Nov 7.

12.

HLA-C Level Is Regulated by a Polymorphic Oct1 Binding Site in the HLA-C Promoter Region.

Vince N, Li H, Ramsuran V, Naranbhai V, Duh FM, Fairfax BP, Saleh B, Knight JC, Anderson SK, Carrington M.

Am J Hum Genet. 2016 Dec 1;99(6):1353-1358. doi: 10.1016/j.ajhg.2016.09.023. Epub 2016 Nov 3.

13.

Activating Receptor Signals Drive Receptor Diversity in Developing Natural Killer Cells.

Freund J, May RM, Yang E, Li H, McCullen M, Zhang B, Lenvik T, Cichocki F, Anderson SK, Kambayashi T.

PLoS Biol. 2016 Aug 8;14(8):e1002526. doi: 10.1371/journal.pbio.1002526. eCollection 2016 Aug. Erratum in: PLoS Biol. 2016 Dec 29;14 (12 ):e1002590.

14.

Analysis of Ly49 gene transcripts in mature NK cells supports a role for the Pro1 element in gene activation, not gene expression.

McCullen MV, Li H, Cam M, Sen SK, McVicar DW, Anderson SK.

Genes Immun. 2016 Sep;17(6):349-57. doi: 10.1038/gene.2016.31. Epub 2016 Jul 28.

15.

Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial.

Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK, Carrero XW, Barker FG 2nd, Deming R, Burri SH, Ménard C, Chung C, Stieber VW, Pollock BE, Galanis E, Buckner JC, Asher AL.

JAMA. 2016 Jul 26;316(4):401-409. doi: 10.1001/jama.2016.9839. Erratum in: JAMA. 2018 Aug 7;320(5):510.

16.

A Novel Three-Dimensional Human Peritubular Microvascular System.

Ligresti G, Nagao RJ, Xue J, Choi YJ, Xu J, Ren S, Aburatani T, Anderson SK, MacDonald JW, Bammler TK, Schwartz SM, Muczynski KA, Duffield JS, Himmelfarb J, Zheng Y.

J Am Soc Nephrol. 2016 Aug;27(8):2370-81. doi: 10.1681/ASN.2015070747. Epub 2015 Dec 11.

17.

Characterization of KIR intermediate promoters reveals four promoter types associated with distinct expression patterns of KIR subtypes.

Li H, Wright PW, McCullen M, Anderson SK.

Genes Immun. 2016 Jan-Feb;17(1):66-74. doi: 10.1038/gene.2015.56. Epub 2015 Dec 10.

18.

Adult patients with supratentorial pilocytic astrocytoma: long-term follow-up of prospective multicenter clinical trial NCCTG-867251 (Alliance).

Brown PD, Anderson SK, Carrero XW, O'Neill BP, Giannini C, Galanis E, Shah SA, Abrams RA, Curran WJ Jr, Buckner JC, Shaw EG.

Neurooncol Pract. 2015 Dec;2(4):199-204. Epub 2015 Aug 6.

19.

The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab.

Huang RY, Rahman R, Ballman KV, Felten SJ, Anderson SK, Ellingson BM, Nayak L, Lee EQ, Abrey LE, Galanis E, Reardon DA, Pope WB, Cloughesy TF, Wen PY.

Clin Cancer Res. 2016 Feb 1;22(3):575-81. doi: 10.1158/1078-0432.CCR-14-3040. Epub 2015 Oct 21.

20.

Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.

Perez EA, Thompson EA, Ballman KV, Anderson SK, Asmann YW, Kalari KR, Eckel-Passow JE, Dueck AC, Tenner KS, Jen J, Fan JB, Geiger XJ, McCullough AE, Chen B, Jenkins RB, Sledge GW, Winer EP, Gralow JR, Reinholz MM.

J Clin Oncol. 2015 Mar 1;33(7):701-8. doi: 10.1200/JCO.2014.57.6298. Epub 2015 Jan 20.

21.

A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K.

Ma DJ, Galanis E, Anderson SK, Schiff D, Kaufmann TJ, Peller PJ, Giannini C, Brown PD, Uhm JH, McGraw S, Jaeckle KA, Flynn PJ, Ligon KL, Buckner JC, Sarkaria JN.

Neuro Oncol. 2015 Sep;17(9):1261-9. doi: 10.1093/neuonc/nou328. Epub 2014 Dec 18.

22.

Interleukin-1 and interferon-γ orchestrate β-glucan-activated human dendritic cell programming via IκB-ζ modulation.

Cardone M, Dzutsev AK, Li H, Riteau N, Gerosa F, Shenderov K, Winkler-Pickett R, Provezza L, Riboldi E, Leighty RM, Orr SJ, Steinhagen F, Wewers MD, Sher A, Anderson SK, Goldszmid R, McVicar DW, Lyakh L, Trinchieri G.

PLoS One. 2014 Dec 4;9(12):e114516. doi: 10.1371/journal.pone.0114516. eCollection 2014.

23.

CMS-required visits adversely impact Seattle area hemodialysis program.

Muczynski KA, Anderson SK.

Nephrol News Issues. 2014 Aug;28(9):32-4.

PMID:
25223075
24.

Exploring primary brain tumor patient and caregiver needs and preferences in brief educational and support opportunities.

Lageman SK, Brown PD, Anderson SK, Lachance DH, Yan E, Laack NN, Cerhan JH.

Support Care Cancer. 2015 Mar;23(3):851-9. doi: 10.1007/s00520-014-2413-y. Epub 2014 Sep 14.

PMID:
25218608
25.

Probabilistic bidirectional promoter switches: noncoding RNA takes control.

Anderson SK.

Mol Ther Nucleic Acids. 2014 Sep 2;3:e191. doi: 10.1038/mtna.2014.42.

26.

Characterization of a weakly expressed KIR2DL1 variant reveals a novel upstream promoter that controls KIR expression.

Wright PW, Li H, Huehn A, O'Connor GM, Cooley S, Miller JS, Anderson SK.

Genes Immun. 2014 Oct;15(7):440-8. doi: 10.1038/gene.2014.34. Epub 2014 Jul 3.

27.

Transcriptional regulation of Munc13-4 expression in cytotoxic lymphocytes is disrupted by an intronic mutation associated with a primary immunodeficiency.

Cichocki F, Schlums H, Li H, Stache V, Holmes T, Lenvik TR, Chiang SC, Miller JS, Meeths M, Anderson SK, Bryceson YT.

J Exp Med. 2014 Jun 2;211(6):1079-91. doi: 10.1084/jem.20131131. Epub 2014 May 19.

28.

Functional NK cell repertoires are maintained through IL-2Rα and Fas ligand.

Felices M, Lenvik TR, Ankarlo DE, Foley B, Curtsinger J, Luo X, Blazar BR, Anderson SK, Miller JS.

J Immunol. 2014 Apr 15;192(8):3889-97. doi: 10.4049/jimmunol.1302601. Epub 2014 Mar 14.

29.

Mutational and structural analysis of KIR3DL1 reveals a lineage-defining allotypic dimorphism that impacts both HLA and peptide sensitivity.

O'Connor GM, Vivian JP, Widjaja JM, Bridgeman JS, Gostick E, Lafont BA, Anderson SK, Price DA, Brooks AG, Rossjohn J, McVicar DW.

J Immunol. 2014 Mar 15;192(6):2875-84. doi: 10.4049/jimmunol.1303142. Epub 2014 Feb 21.

30.

Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer.

Purrington KS, Slager S, Eccles D, Yannoukakos D, Fasching PA, Miron P, Carpenter J, Chang-Claude J, Martin NG, Montgomery GW, Kristensen V, Anton-Culver H, Goodfellow P, Tapper WJ, Rafiq S, Gerty SM, Durcan L, Konstantopoulou I, Fostira F, Vratimos A, Apostolou P, Konstanta I, Kotoula V, Lakis S, Dimopoulos MA, Skarlos D, Pectasides D, Fountzilas G, Beckmann MW, Hein A, Ruebner M, Ekici AB, Hartmann A, Schulz-Wendtland R, Renner SP, Janni W, Rack B, Scholz C, Neugebauer J, Andergassen U, Lux MP, Haeberle L, Clarke C, Pathmanathan N, Rudolph A, Flesch-Janys D, Nickels S, Olson JE, Ingle JN, Olswold C, Slettedahl S, Eckel-Passow JE, Anderson SK, Visscher DW, Cafourek VL, Sicotte H, Prodduturi N, Weiderpass E, Bernstein L, Ziogas A, Ivanovich J, Giles GG, Baglietto L, Southey M, Kosma VM, Fischer HP; GENICA Network, Reed MW, Cross SS, Deming-Halverson S, Shrubsole M, Cai Q, Shu XO, Daly M, Weaver J, Ross E, Klemp J, Sharma P, Torres D, Rüdiger T, Wölfing H, Ulmer HU, Försti A, Khoury T, Kumar S, Pilarski R, Shapiro CL, Greco D, Heikkilä P, Aittomäki K, Blomqvist C, Irwanto A, Liu J, Pankratz VS, Wang X, Severi G, Mannermaa A, Easton D, Hall P, Brauch H, Cox A, Zheng W, Godwin AK, Hamann U, Ambrosone C, Toland AE, Nevanlinna H, Vachon CM, Couch FJ.

Carcinogenesis. 2014 May;35(5):1012-9. doi: 10.1093/carcin/bgt404. Epub 2013 Dec 9.

31.

An integrated model of the transcriptome of HER2-positive breast cancer.

Kalari KR, Necela BM, Tang X, Thompson KJ, Lau M, Eckel-Passow JE, Kachergus JM, Anderson SK, Sun Z, Baheti S, Carr JM, Baker TR, Barman P, Radisky DC, Joseph RW, McLaughlin SA, Chai HS, Camille S, Rossell D, Asmann YW, Thompson EA, Perez EA.

PLoS One. 2013 Nov 1;8(11):e79298. doi: 10.1371/journal.pone.0079298. eCollection 2013.

32.

Differential expression of the Ly49G(B6), but not the Ly49G(BALB), receptor isoform during natural killer cell reconstitution after hematopoietic stem cell transplantation.

Barao I, Wright PW, Sungur CM, Anderson SK, Redelman D, Murphy WJ.

Biol Blood Marrow Transplant. 2013 Oct;19(10):1446-52. doi: 10.1016/j.bbmt.2013.07.021. Epub 2013 Jul 31.

33.

Identification of a KIR antisense lncRNA expressed by progenitor cells.

Wright PW, Huehn A, Cichocki F, Li H, Sharma N, Dang H, Lenvik TR, Woll P, Kaufman D, Miller JS, Anderson SK.

Genes Immun. 2013 Oct;14(7):427-33. doi: 10.1038/gene.2013.36. Epub 2013 Jul 18.

34.

Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial.

Galanis E, Anderson SK, Lafky JM, Uhm JH, Giannini C, Kumar SK, Kimlinger TK, Northfelt DW, Flynn PJ, Jaeckle KA, Kaufmann TJ, Buckner JC.

Clin Cancer Res. 2013 Sep 1;19(17):4816-23. doi: 10.1158/1078-0432.CCR-13-0708. Epub 2013 Jul 5.

35.

Contrasting effects of anti-Ly49A due to MHC class I cis binding on NK cell-mediated allogeneic bone marrow cell resistance.

Alvarez M, Sungur CM, Ames E, Anderson SK, Pomeroy C, Murphy WJ.

J Immunol. 2013 Jul 15;191(2):688-98. doi: 10.4049/jimmunol.1300202. Epub 2013 Jun 10.

36.

LAB/NTAL facilitates fungal/PAMP-induced IL-12 and IFN-γ production by repressing β-catenin activation in dendritic cells.

Orr SJ, Burg AR, Chan T, Quigley L, Jones GW, Ford JW, Hodge D, Razzook C, Sarhan J, Jones YL, Whittaker GC, Boelte KC, Lyakh L, Cardone M, O'Connor GM, Tan C, Li H, Anderson SK, Jones SA, Zhang W, Taylor PR, Trinchieri G, McVicar DW.

PLoS Pathog. 2013 May;9(5):e1003357. doi: 10.1371/journal.ppat.1003357. Epub 2013 May 9.

37.

Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.

Cen L, Carlson BL, Pokorny JL, Mladek AC, Grogan PT, Schroeder MA, Decker PA, Anderson SK, Giannini C, Wu W, Ballman KV, Kitange GJ, Sarkaria JN.

Neuro Oncol. 2013 Jun;15(6):735-46. doi: 10.1093/neuonc/not010. Epub 2013 Mar 10.

38.

Epigenetic regulation of NK cell differentiation and effector functions.

Cichocki F, Miller JS, Anderson SK, Bryceson YT.

Front Immunol. 2013 Feb 28;4:55. doi: 10.3389/fimmu.2013.00055. eCollection 2013.

39.

Quality assessment metrics for whole genome gene expression profiling of paraffin embedded samples.

Mahoney DW, Therneau TM, Anderson SK, Jen J, Kocher JP, Reinholz MM, Perez EA, Eckel-Passow JE.

BMC Res Notes. 2013 Jan 30;6:33. doi: 10.1186/1756-0500-6-33.

40.

Mouse Nkrp1-Clr gene cluster sequence and expression analyses reveal conservation of tissue-specific MHC-independent immunosurveillance.

Zhang Q, Rahim MM, Allan DS, Tu MM, Belanger S, Abou-Samra E, Ma J, Sekhon HS, Fairhead T, Zein HS, Carlyle JR, Anderson SK, Makrigiannis AP.

PLoS One. 2012;7(12):e50561. doi: 10.1371/journal.pone.0050561. Epub 2012 Dec 4.

41.

CD8 T cells express randomly selected KIRs with distinct specificities compared with NK cells.

Björkström NK, Béziat V, Cichocki F, Liu LL, Levine J, Larsson S, Koup RA, Anderson SK, Ljunggren HG, Malmberg KJ.

Blood. 2012 Oct 25;120(17):3455-65. doi: 10.1182/blood-2012-03-416867. Epub 2012 Sep 11.

42.

Promoter variants in the MSMB gene associated with prostate cancer regulate MSMB/NCOA4 fusion transcripts.

Lou H, Li H, Yeager M, Im K, Gold B, Schneider TD, Fraumeni JF Jr, Chanock SJ, Anderson SK, Dean M.

Hum Genet. 2012 Sep;131(9):1453-1466. doi: 10.1007/s00439-012-1182-2. Epub 2012 Jun 4.

43.

Undergraduate physical activity and depressive symptoms: a national study.

Elliot CA, Kennedy C, Morgan G, Anderson SK, Morris D.

Am J Health Behav. 2012 Mar;36(2):230-41. doi: 10.5993/AJHB.36.2.8.

PMID:
22370260
44.

Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study.

Friday BB, Anderson SK, Buckner J, Yu C, Giannini C, Geoffroy F, Schwerkoske J, Mazurczak M, Gross H, Pajon E, Jaeckle K, Galanis E.

Neuro Oncol. 2012 Feb;14(2):215-21. doi: 10.1093/neuonc/nor198. Epub 2011 Nov 16.

45.

Mouse Ly49G2+ NK cells dominate early responses during both immune reconstitution and activation independently of MHC.

Barao I, Alvarez M, Ames E, Orr MT, Stefanski HE, Blazar BR, Lanier LL, Anderson SK, Redelman D, Murphy WJ.

Blood. 2011 Jun 30;117(26):7032-41. doi: 10.1182/blood-2010-11-316653. Epub 2011 Apr 15.

46.

Killer immunoglobulin-like receptor transcriptional regulation: a fascinating dance of multiple promoters.

Cichocki F, Miller JS, Anderson SK.

J Innate Immun. 2011;3(3):242-8. doi: 10.1159/000323929. Epub 2011 Mar 11. Review.

47.

Identification of a clinically relevant androgen-dependent gene signature in prostate cancer.

Heemers HV, Schmidt LJ, Sun Z, Regan KM, Anderson SK, Duncan K, Wang D, Liu S, Ballman KV, Tindall DJ.

Cancer Res. 2011 Mar 1;71(5):1978-88. doi: 10.1158/0008-5472.CAN-10-2512. Epub 2011 Feb 15.

48.

C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.

Perez EA, Jenkins RB, Dueck AC, Wiktor AE, Bedroske PP, Anderson SK, Ketterling RP, Sukov WR, Kanehira K, Chen B, Geiger XJ, Andorfer CA, McCullough AE, Davidson NE, Martino S, Sledge GW, Kaufman PA, Kutteh LA, Gralow JR, Harris LN, Ingle JN, Lingle WL, Reinholz MM.

J Clin Oncol. 2011 Feb 20;29(6):651-9. doi: 10.1200/JCO.2010.30.2125. Epub 2011 Jan 18.

49.

Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL® platform.

Reinholz MM, Eckel-Passow JE, Anderson SK, Asmann YW, Zschunke MA, Oberg AL, McCullough AE, Dueck AC, Chen B, April CS, Wickham-Garcia E, Jenkins RB, Cunningham JM, Jen J, Perez EA, Fan JB, Lingle WL.

BMC Med Genomics. 2010 Dec 20;3:60. doi: 10.1186/1755-8794-3-60.

50.

A novel role for IL-22R1 as a driver of inflammation.

Savan R, McFarland AP, Reynolds DA, Feigenbaum L, Ramakrishnan K, Karwan M, Shirota H, Klinman DM, Dunleavy K, Pittaluga S, Anderson SK, Donnelly RP, Wilson WH, Young HA.

Blood. 2011 Jan 13;117(2):575-84. doi: 10.1182/blood-2010-05-285908. Epub 2010 Oct 22.

Supplemental Content

Loading ...
Support Center